help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vlahovic, G.
Right arrow Articles by Crawford, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vlahovic, G.
Right arrow Articles by Crawford, J.
The Oncologist, Vol. 8, No. 6, 531–538, December 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
Clinical Pharmacology

Activation of Tyrosine Kinases in Cancer

Gordana Vlahovic, Jeffrey Crawford

Duke University Medical Center, Division of Hematology/Oncology, Durham, North Carolina, USA

Correspondence: Jeffrey Crawford, M.D., Duke University Medical Center, Box 3198, Morris Building, Room 25178, Durham, North Carolina 27710, USA. Telephone: 919-684-5195; Fax: 919-681-5864; e-mail: crawf006{at}mc.duke.edu

Receptor and nonreceptor tyrosine kinases (TKs) have emerged as clinically useful drug target molecules for treating certain types of cancer. Epidermal growth factor receptor (EGFR)-TK is a transmembrane receptor TK that is overexpressed or aberrantly activated in the most common solid tumors, including non-small cell lung cancer and cancers of the breast, prostate, and colon. Activation of the EGFR-TK enzyme results in autophosphorylation, which drives signal transduction pathways leading to tumor growth and malignant progression. Randomized clinical trials of the EGFR-TK inhibitor gefitinib have demonstrated clinical benefits in patients with advanced non-small cell lung cancer whose disease had previously progressed on platinum- and docetaxel-based chemotherapy regimens. Bcr-Abl is a constitutively activated nonreceptor TK enzyme found in the cytoplasm of Philadelphia chromosome-positive leukemia cells. STI571 (imatinib mesylate) inhibits the Bcr-Abl TK, blocks the growth of these leukemia cells, and induces apoptosis. STI571 also inhibits other TKs, including the receptor TK c-kit, which is expressed in gastrointestinal stromal tumors. As TK inhibitors become available for clinical use, new challenges include predicting which patients are most likely to respond to these targeted TK inhibitors. Additional clinical trials are needed to develop the full potential of receptor and nonreceptor TK inhibitors for cancer treatment.

Key Words. Tyrosine kinase • Cancer • Epidermal growth factor receptor-tyrosine kinase • Bcr-Abl • Gefitinib • STI571




This article has been cited by other articles:


Home page
Cancer Genomics ProteomicsHome page
N. VALERI, C. M. CROCE, and M. FABBRI
Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer
Cancer Genomics Proteomics, July 1, 2009; 6(4): 195 - 204.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
B. Nagar
c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571)
J. Nutr., June 1, 2007; 137(6): 1518S - 1523S.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy
Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS
J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev., August 1, 2006; 27(5): 535 - 560.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. J. Delfino, H. Stevenson, and T. E. Smithgall
A Growth-suppressive Function for the c-Fes Protein-Tyrosine Kinase in Colorectal Cancer
J. Biol. Chem., March 31, 2006; 281(13): 8829 - 8835.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms.
Cancer Res., March 15, 2006; 66(6): 3197 - 3204.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. S. Benjamin, C. D. Blanke, J.-Y. Blay, S. Bonvalot, and B. Eisenberg
Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies
Oncologist, January 1, 2006; 11(1): 9 - 20.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Cutcliffe, D. Kersey, C.-C. Huang, Y. Zeng, D. Walterhouse, E. J. Perlman, and for the Renal Tumor Committee of the Children's On
Clear Cell Sarcoma of the Kidney: Up-regulation of Neural Markers with Activation of the Sonic Hedgehog and Akt Pathways
Clin. Cancer Res., November 15, 2005; 11(22): 7986 - 7994.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
A. Shrivastava, M.A. von Wronski, A.K. Sato, D.T. Dransfield, D. Sexton, N. Bogdan, R. Pillai, P. Nanjappan, B. Song, E. Marinelli, et al.
A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases
Protein Eng. Des. Sel., September 1, 2005; 18(9): 417 - 424.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
L. Yang, C. Lin, and Z.-R. Liu
Phosphorylations of DEAD Box p68 RNA Helicase Are Associated with Cancer Development and Cell Proliferation
Mol. Cancer Res., June 1, 2005; 3(6): 355 - 363.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M.-C. Etienne-Grimaldi, S. Pereira, N. Magne, J.-L. Formento, M. Francoual, X. Fontana, F. Demard, O. Dassonville, G. Poissonnet, J. Santini, et al.
Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients
Ann. Onc., June 1, 2005; 16(6): 934 - 941.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.